<DOC>
	<DOCNO>NCT01643785</DOCNO>
	<brief_summary>Endonase , kind protease , know cause extensive degradation mucin reduction mucus viscosity . As part search effective form therapy H. pylorus colonize surface surface mucosal cell also surface mucous gel layer cover mucosal surface stomach . The investigator decide investigate whether endonase might additive effect pronase efficacy second-line eradication therapy Helicobacter pylorus .</brief_summary>
	<brief_title>Additive Effect Endonase Eradication Rate Second Line Therapy HP Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<criteria>Patients 18 year age AND Patients fail standard proton pump inhibitorbased triple therapy H. pylori 1 . Patients Under 18 year , OR 2 . Patients active peptic ulcer , OR 3 . Pregnant Breast feeding woman , OR 4 . Patients gastric malignancy , OR 5 . Patients history drug allergy hypersensitivity , OR 6 . Patients severe renal , liver , heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>therapeutic efficacy endonase addictive effect</keyword>
</DOC>